137 related articles for article (PubMed ID: 7981461)
1. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.
Watts CK; Sweeney KJ; Warlters A; Musgrove EA; Sutherland RL
Breast Cancer Res Treat; 1994; 31(1):95-105. PubMed ID: 7981461
[TBL] [Abstract][Full Text] [Related]
2. Chaperonin CCT-mediated AIB1 folding promotes the growth of ERα-positive breast cancer cells on hard substrates.
Chen L; Zhang Z; Qiu J; Zhang L; Luo X; Jang J
PLoS One; 2014; 9(5):e96085. PubMed ID: 24788909
[TBL] [Abstract][Full Text] [Related]
3. Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression.
Meng C; Zou Y; Hong W; Bao C; Jia X
Mol Med; 2020 Apr; 26(1):33. PubMed ID: 32272902
[TBL] [Abstract][Full Text] [Related]
4. Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence.
Čižmáriková M; Michalková R; Mirossay L; Mojžišová G; Zigová M; Bardelčíková A; Mojžiš J
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002335
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic resistance to anti-oestrogen therapy in breast cancer.
Will M; Liang J; Metcalfe C; Chandarlapaty S
Nat Rev Cancer; 2023 Oct; 23(10):673-685. PubMed ID: 37500767
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer-A Review of the Literature.
Stanciu IM; Parosanu AI; Orlov-Slavu C; Iaciu IC; Popa AM; Olaru CM; Pirlog CF; Vrabie RC; Nitipir C
Diagnostics (Basel); 2023 Mar; 13(5):. PubMed ID: 36900131
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
Tsuji J; Li T; Grinshpun A; Coorens T; Russo D; Anderson L; Rees R; Nardone A; Patterson C; Lennon NJ; Cibulskis C; Leshchiner I; Tayob N; Tolaney SM; Tung N; McDonnell DP; Krop IE; Winer EP; Stewart C; Getz G; Jeselsohn R
Clin Cancer Res; 2022 Dec; 28(23):5066-5078. PubMed ID: 36215125
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers.
Reddy S; Barkhane Z; Elmadi J; Satish Kumar L; Pugalenthi LS; Ahmad M
Cureus; 2022 Apr; 14(4):e23901. PubMed ID: 35530846
[TBL] [Abstract][Full Text] [Related]
9. The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.
Wang Y; Yuan X; Li J; Liu Z; Li X; Wang Z; Wei L; Li Y; Wang X
Front Cell Dev Biol; 2021; 9():785796. PubMed ID: 34977029
[TBL] [Abstract][Full Text] [Related]
10. Effect of d-limonene and its derivatives on breast cancer in human trials: a scoping review and narrative synthesis.
Chebet JJ; Ehiri JE; McClelland DJ; Taren D; Hakim IA
BMC Cancer; 2021 Aug; 21(1):902. PubMed ID: 34362338
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment.
Scheiblecker L; Kollmann K; Sexl V
Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33255177
[TBL] [Abstract][Full Text] [Related]
12. Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.
Grizzi G; Ghidini M; Botticelli A; Tomasello G; Ghidini A; Grossi F; Fusco N; Cabiddu M; Savio T; Petrelli F
Cancer Manag Res; 2020; 12():675-686. PubMed ID: 32099464
[TBL] [Abstract][Full Text] [Related]
13. Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers.
Elmi A; McDonald ES; Mankoff D
PET Clin; 2018 Jul; 13(3):445-457. PubMed ID: 30100082
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Goel S; DeCristo MJ; McAllister SS; Zhao JJ
Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibition in breast cancer: current practice and future directions.
Pernas S; Tolaney SM; Winer EP; Goel S
Ther Adv Med Oncol; 2018; 10():1758835918786451. PubMed ID: 30038670
[TBL] [Abstract][Full Text] [Related]
16. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
17. Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Bernhardt SM; Dasari P; Walsh D; Townsend AR; Price TJ; Ingman WV
Front Oncol; 2016; 6():241. PubMed ID: 27896218
[TBL] [Abstract][Full Text] [Related]
18. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.
Ronghe A; Chatterjee A; Bhat NK; Padhye S; Bhat HK
Oncotarget; 2016 Aug; 7(32):51747-51762. PubMed ID: 27351134
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
Finn RS; Aleshin A; Slamon DJ
Breast Cancer Res; 2016 Feb; 18(1):17. PubMed ID: 26857361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
